Jerry Avorn

Dec 30, 2024 | bmj.com | William B. Feldman |Samy Suissa |Aaron S. Kesselheim |Jerry Avorn

Research BMJ 2024; 387 doi: https://doi.org/10.1136/bmj-2024-080409 Cite this as: BMJ 2024;387:e080409 Linked Editorial Environmentally friendly inhaler regimens for COPD William B Feldman, assistant professor1 2 3, Samy Suissa, professor4, Aaron S Kesselheim, professor1 3, Jerry Avorn, professor1 3, Massimiliano Russo, assistant professor5, Sebastian Schneeweiss, professor1 3, Shirley V Wang, associate professor1 3 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of...

Jun 5, 2024 | dialnet.unirioja.es | Alexander C. Egilman |Aaron S. Kesselheim |Jerry Avorn |Adam J. N

Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque PsoriasisAutores: Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn, Adam J. N. Raymakers, Benjamin N. RomeLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 4, 2024, págs. 409-416Idioma: inglésEnlacesTexto completoResumenImportance The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles.

Apr 4, 2024 | jamanetwork.com | Thomas Hwang |Jerry Avorn |Aaron S. Kesselheim

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies Key PointsQuestion  What is the validity of the molecular targets and clinical benefits of US Food and Drug Administration–approved genome-targeted cancer drugs based on the results of pivotal clinical trials? Findings  In this cohort study, 50 molecular-targeted drugs covering 84 indications were identified.

Feb 21, 2024 | jamanetwork.com | Alexander C. Egilman |Aaron S. Kesselheim |Jerry Avorn

Key PointsQuestion  How could an efficiency frontier approach be used to better align prices with the clinical efficacy of biologic medications for plaque psoriasis? Findings  In this economic evaluation, US net prices of 13 biologic therapies for psoriasis ranged from $1664 to $79 277 per year, and clinical efficacy measured by Psoriasis Area Severity Index 90 scores ranged from 17.9% to 71.6%.

Feb 20, 2024 | healthaffairs.org | Jerry Avorn |Aaron S. Kesselheim

Americans pay twice as much per capita for their brand-name drugs as people in other wealthy countries, making medications less affordable as well as driving up the cost of health care and its funding through premiums and taxes. Yet our health outcomes are about average or a little worse than those of our peer nations. More than a quarter of patients report being unable to pay for the medicines we prescribe for them.